Quarterly Updates19 May 2026, 08:11 pm
Anthem Biosciences: FY26 Revenue from Operations at ₹21,243.33 Mn
AI Summary
Anthem Biosciences Ltd reports key performance indicators for the financial year 2025-26. Total revenue from operations reached ₹21,243.33 million, with a year-on-year growth of 15.17%. Revenue from Contract Research, Developmental & Commercial Manufacturing (CRDMO) stood at ₹17,727.68 million, while revenue from Specialty Ingredients (SI) was ₹3,515.65 million. The ratio of revenue from operations from CRDMO: SI was 83:17. EBITDA was ₹8,971.69 million with a margin of 47.07%, and PAT was ₹5,917.92 million with a margin of 25.95%.
Key Highlights
- Total revenue from operations for FY26 reached ₹21,243.33 million, a 15.17% YoY growth.
- CRDMO revenue contributed ₹17,727.68 million, while Specialty Ingredients generated ₹3,515.65 million.
- EBITDA stood at ₹8,971.69 million with a margin of 47.07%.
- PAT was ₹5,917.92 million, resulting in a PAT margin of 25.95%.
- Material Margin was ₹13,120.50 million, representing 61.76%.
Price Impact
More from ANTHEM